GV, Tencent and Gilead Sciences will exit the vaccine and infectious disease drug developer in an initial public offering sized at about $110m.

Vaccitech, a UK-based vaccine developer that counts corporates Tencent, Alphabet, and Gilead Sciences as investors, will raise about $110m when it begins trading on the Nasdaq Global Market today. The company will issue 6.5 million American Depositary Shares (ADSs), each representing one ordinary share. It priced them at $17.00 each, at the midpoint of the…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.